Man Group
PSTX

Man Group’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Man Group’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-34,171
Closed -$97.7K – 2252
2024
Q3 		$97.7K Sell
34,171
-46,405
-58% -$144K ﹤0.01% 1904
2024
Q2 		$235K Buy
80,576
+939
+1% +$2.57K ﹤0.01% 1852
2024
Q1 		$254K Buy
+79,637
New +$266K ﹤0.01% 1964
2023
Q3 		– Sell
-31,450
Closed -$55.4K – 2212
2023
Q2 		$55.4K Buy
+31,450
New +$80.3K ﹤0.01% 1911
2023
Q1 		– Sell
-27,663
Closed -$166K – 1969
2022
Q4 		$147K Buy
27,663
+15,647
+130% +$71.5K ﹤0.01% 1830
2022
Q3 		$42K Buy
+12,016
New +$39.7K ﹤0.01% 1908

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Man Group's PSTX Position: Q4 2024 in Review

Man Group sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2024, closing a stake of 34,171 shares — an estimated $97.7K sold.

Man Group first reported a position in PSTX in Q3 2022 and held it in 6 quarters. The position peaked at $254K in Q1 2024. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

  • Man Group reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Man Group sold 34,171 Poseida Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $97.7K.
  • Man Group first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2022 and held it in 6 quarters.
  • Man Group's Poseida Therapeutics, Inc. Common Stock position peaked at $254K in Q1 2024.
  • 115 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Man Group's 13F filing for Q4 2024, filed 14 Feb 2025.